ÀÖ²¥´«Ã½

Skip to Content on ÀÖ²¥´«Ã½.org
You're location is
All Regions
ÀÖ²¥´«Ã½r
Locations
Closeup of a person holding a phone using the ÀÖ²¥´«Ã½ app.

We Make Health Care Easy With the ÀÖ²¥´«Ã½ App

Access communications, appointment and symptom tracking and more.

Online Bill Pay

Paying a bill online is easy and secure.

Learn More

Send a Free E-Card

Brighten the day of your loved one staying at one of our hospitals. 

Give It a Try
Young child posing with arms out like he is flying.

KidsHealth Library

Healthy living for parents, kids and teens.

Meet Our Team

Learn more about our physician researchers, clinicians and scientists.

Find a Researcher
# #

    Robin E. Miller, MD

    Pediatric Hematologist
    Provider Profile

    ÀÖ²¥´«Ã½ Children's Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803

    Biography

    Robin Miller, MD is a Pediatric Hematologist/Oncologist at ÀÖ²¥´«Ã½ Children's Hospital, Delaware (NCH-DE) and Clinical Associate Professor at Jefferson Medical College. She received her bachelor's degree from John's Hopkins University and medical degree from Temple University. After that she completed a Pediatric Residency and fellowship in Pediatric Hematology/Oncology at Rainbow Babies and Children's Hospital in Cleveland, OH. Dr. Miller came to NCH-DE in 2001. Since then, she has been the director of the Sickle Cell Disease multidisciplinary clinic and the main focus of her research is Sickle Cell Disease treatment and quality improvement. She has worked extensively to build the Sickle Cell research capacity at ÀÖ²¥´«Ã½. She is involved medical student, resident and fellow teaching as well as mentoring of junior investigators.

    Fellowship

    • Pediatric Hematology/Oncology - Rainbow Babies & Children's Hospital, 1996

    Internship

    • Pediatrics - Rainbow Babies & Children's Hospital, 1990

    Residency

    • Pediatrics - Rainbow Babies & Children's Hospital, 1993

    Medical/Dental School

    • MD - Temple University School of Medicine, 1989

    Board Certifications

    • American Board of Pediatrics/Hematology-Oncology

    • Hematology
    • Pediatric
    • Sickle Cell

    • Monitoring retinal pathology and cerebral injury in sickle cell disease using spectral-domain optical coherence tomography in pediatric patients; Pediatric Blood and Cancer; (2021).

    • Psychosocial screening in sickle cell disease: Validation of the psychosocial assessment tool; Journal of Pediatric Psychology; (2020).

    • A Complicated Case of Vaccine Refusal; Pediatrics; (2020).

    • Family Resilience from the Perspective of Caregivers of Youth with Sickle Cell Disease; Journal of Pediatric Hematology/Oncology; (2020).

    • Implementation of a learning healthcare system for sickle cell disease; JAMIA Open; (2020).

    • Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia; Prostaglandins Leukotrienes and Essential Fatty Acids; (2019).

    • Quantitative sensory testing in children with sickle cell disease: additional insights and future possibilities; British Journal of Haematology; (2019).

    • Funduscopic examination and SD-OCT in detecting sickle cell retinopathy among pediatric patients; Journal of AAPOS; (2018).

    • Caregiver perspectives on family psychosocial risks and resiliencies in pediatric sickle cell disease: Informing the adaptation of the Psychosocial Assessment Tool.; Clinical Practice in Pediatric Psychology; (2017).

    • Posterior reversible encephalopathy syndrome and cerebral sinus thrombosis in a case of pediatric B-Cell ALL; Journal of Pediatric Hematology/Oncology; (2017).

    • Loss of Major DNase I Hypersensitive Sites in Duplicated β-globin Gene Cluster Incompletely Silences HBB Gene Expression; Human Mutation; (2016).

    • Update on Pediatric Leukemia and Lymphoma Imaging; Seminars in Ultrasound, CT and MRI; (2013).

    • Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: Results of a feasibility study (PROACTIVE); British Journal of Haematology; (2012).

    • Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease; Pediatric Blood and Cancer; (2012).

    • A rare case of osteosarcoma and rhabdomyosarcoma at the same site 7 years apart.; American journal of orthopedics (Belle Mead, N.J.); (2008).

    • Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45; Journal of Biological Chemistry; (2003).

    • Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation; Blood; (2003).

    • Reduced CTLA-4 protein and messenger RNA expression in umbilical cord blood T lymphocytes; Experimental Hematology; (2002).

    • Cyclosporin A effects during primary and secondary activation of human umbilical cord blood T lymphocytes; Experimental Hematology; (2001).

    • Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes; Blood; (1999).

    • A receptor for the lipocalin placental protein 14 on human monocytes; FEBS Letters; (1998).

    • Transient erythroblastopenia of childhood in infants 6 months of age; Journal of Pediatric Hematology/Oncology; (1994).